![]() |
市场调查报告书
商品编码
1477937
连续血糖监测系统市场预测:~2032 年Continuous Glucose Monitoring System Market Research Report Forecast till 2032 |
在预测期内,连续血糖监测系统市场规模预计将以 11.24% 的复合年增长率成长。
糖尿病盛行率的增加是推动全球连续血糖监测系统市场成长的一个突出因素。 患有糖尿病的人数正以惊人的速度增加,达到流行病的程度。 根据全球糖尿病联盟 (IDF) 的数据,2021 年全球约有 5.37 亿人患有糖尿病,预计到 2030 年这一数字将跃升至 6.43 亿。 此外,根据美国糖尿病协会的数据,到 2021 年,将有 3,840 万美国人(占总人口的 11.6%)患有糖尿病。 1 型糖尿病影响着约 200 万美国人,其中包括约 304,000 名儿童和青少年。 随着糖尿病人口的持续增长,对有效的糖尿病管理解决方案的需求变得更加迫切。 连续血糖监测系统在即时瞭解血糖水平方面发挥着至关重要的作用,使患者和医疗保健专业人员能够就治疗和生活方式的改变做出及时、明智的决定。 连续血糖监测系统提供连续监测、早期异常检测和个人化见解的能力满足了不断增长的糖尿病族群的需求。
区域见解
北美连续血糖监测系统市场预计到 2023 年将达到 30.7 亿美元,在预测期内复合年增长率为 10.06%。
在技术进步和该地区糖尿病盛行率上升的推动下,北美的连续血糖监测系统市场正在经历强劲增长。
由于技术进步、医疗成本增加和糖尿病盛行率增加,欧洲连续血糖监测系统市场占据第二大市场。由于患者人数众多、临床试验成本较低以及有利的监管政策,亚太地区连续血糖监测系统市场预计将在 2023 年至 2030 年期间成长最快。 此外,各大公司积极向该地区扩张也推动了该地区的市场成长。
本报告调查了全球连续血糖监测系统市场,提供了市场的定义和概述,分析了影响市场成长的因素和市场机会、市场规模、各个细分市场/地区/主要的趋势和预测,它总结了细分:国家、竞争环境和主要公司概况。
Download PDF
Continuous Glucose Monitoring System Market is projected to register a CAGR of 11.24% during the review period.
The rising pervasiveness of diabetes overall stands apart as a conspicuous driver energizing the development of the worldwide continuous glucose monitoring systems market. Diabetes has arrived at plague extents, with a stunning ascent in the quantity of impacted people universally. As per the Global Diabetes Alliance (IDF), in 2021, roughly 537 million individuals overall were living with diabetes, and this number is supposed to take off to 643 million by 2030. Essentially, as per the American Diabetes Affiliation, diabetes impacted 38.4 million Americans, or 11.6% of the populace, in 2021. Type 1 diabetes influences around 2.0 million Americans, including roughly 304,000 youngsters and teenagers. The heightening rate of diabetes is ascribed to different elements, including stationary ways of life, unfortunate dietary propensities, and the maturing populace. As the diabetic populace keeps on developing, the interest for powerful diabetes the board arrangements turn out to be really squeezing. Continuous glucose monitoring systems assume a vital part in giving constant experiences into blood glucose levels, empowering patients and medical care experts to settle on convenient and informed choices in regard to therapy and way of life changes. The capacity of continuous glucose monitoring systems to offer continuous monitoring, early discovery of variances, and customized bits of knowledge lines up with the developing requirements of the extending diabetic populace.
Based on product the continuous glucose monitoring system market is divided into sensors and transmitter and receivers.
In terms of application, the market is classified into type 2 diabetes, type 1 diabetes, and non-diabetic patients.
Based on End user, the market has been divided into hospitals & clinics, homecare settings, and others.
Regional Insights
The North America continuous glucose monitoring systems market represented USD 3.07 billion out of 2023 and is projected to develop at a CAGR of 10.06% during the figure time frame. North America is additionally fragmented into the US, and Canada.
The North America continuous glucose monitoring systems market is encountering strong development, driven by mechanical progressions and a rising predominance of diabetes in the region.
Europe continuous glucose monitoring System market represented the second-biggest market share because of innovation progressions, expanding medical care consumption, and expanding pervasiveness of diabetes.
The Asia-Pacific Continuous Glucose Monitoring System market is supposed to be the quickest developing from 2023 to 2030 attributable to high persistent populace, decreased expenses of leading preliminaries, and good administrative arrangements. In addition, central participants working in the Continuous Glucose Monitoring System Market are effectively venturing into this region, further driving the regional market development.
Key Companies operating in the Continuous Glucose Monitoring System market are Dexcom, Inc (US), Menarini Diagnostics Srl (Italy), Senseonics (US), Medtrum Technologies Inc. (China), Nemaura Medical Inc (US), Ultrahuman Healthcare Pvt Ltd (India), Medtronic (Ireland), One Drop (US), Abbott Laboratories, Inc. (US), and Sinocare (China).
MARKET